Therapeutic preparedness: DAA-resistant HCV variants in vitro and in vivo

Julia Dietz^{1

2}, Volker Lohmann^{3

4}

Affiliations

¹ Department of Internal Medicine 1, University Hospital, Goethe University, Frankfurt, Germany.
² German Center for Infection Research (DZIF), External Partner Site Frankfurt, Germany.
³ Department of Infectious Diseases, Heidelberg University, Medical Faculty Heidelberg, Molecular Virology, Section Virus-Host-Interactions, Center for Integrative Infectious Disease Research, Heidelberg, Germany.
⁴ German Centre for Infection Research (DZIF), Partner Site Heidelberg, Heidelberg, Germany.

Editorial

Julia Dietz et al. Hepatology. 2023.

. 2023 Aug 1;78(2):385-387.

doi: 10.1097/HEP.0000000000000405. Epub 2023 Apr 15.

Julia Dietz^{1

2}, Volker Lohmann^{3

4}

¹ Department of Internal Medicine 1, University Hospital, Goethe University, Frankfurt, Germany.
² German Center for Infection Research (DZIF), External Partner Site Frankfurt, Germany.
³ Department of Infectious Diseases, Heidelberg University, Medical Faculty Heidelberg, Molecular Virology, Section Virus-Host-Interactions, Center for Integrative Infectious Disease Research, Heidelberg, Germany.
⁴ German Centre for Infection Research (DZIF), Partner Site Heidelberg, Heidelberg, Germany.

No abstract available

Comment on

Virological characterization of treatment failures and retreatment outcomes in patients infected with "unusual" HCV genotype 1 subtypes.
Vo-Quang E, Soulier A, Ndebi M, Rodriguez C, Chevaliez S, Leroy V, Fourati S, Pawlotsky JM; EPIRES-C ANRS/MIE Study Group. Vo-Quang E, et al. Hepatology. 2023 Aug 1;78(2):607-620. doi: 10.1097/HEP.0000000000000379. Epub 2023 Apr 1. Hepatology. 2023. PMID: 36999537
Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
Fernandez-Antunez C, Wang K, Fahnøe U, Mikkelsen LS, Gottwein JM, Bukh J, Ramirez S. Fernandez-Antunez C, et al. Hepatology. 2023 Aug 1;78(2):621-636. doi: 10.1097/HEP.0000000000000353. Epub 2023 Apr 3. Hepatology. 2023. PMID: 36999539

1. Sarrazin C. Treatment failure with DAA therapy: importance of resistance. J Hepatol. 2021;74:1472–1482.
1. Gottwein JM, Scheel TK, Callendret B, Li YP, Eccleston HB, Engle RE, et al. Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol. 2010;84:5277–5293.
1. Fernandez-Antunez C, Wang K, Fahnoe U, Mikkelsen LS, Gottwein JM, Bukh J, et al. Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system. Hepatology. 2023;78:621–636.
1. Howe AYM, Rodrigo C, Cunningham EB, Douglas MW, Dietz J, Grebely J, et al. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Rep. 2022;4:100462.
1. Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paolucci S, et al. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. J Hepatol. 2021;74:801–810.